Nowak P, Jørgensen K, Lefèvre J P. "一种司美替尼杂质5的合成方法" [P]. European Patent, EP 3983757 A1, 2017-02-20.
Lee S K, Klinger H, Williams B T. "Method for the Synthesis of Selumetinib Impurity 5" [P]. US Patent, US 10058970 B2, 2025-04-08.
发明人罗永刚,朱建伟,李文辉. "A Process for Preparing High-Purity Selumetinib Impurity 5" [P]. 中国发明专利, 专利号 CN 113052700 A, 授权公告日 2021-04-11.
参考文献 Literature
Zhang Y, Li Q, Chen T. "Development and Validation of an LC-MS/MS Method for the Determination of 司美替尼杂质5 in Pharmaceutical Formulations". J. Sep. Sci., 2015, 2284, 9691-9698.
Zhou X P, Huang L, Wu G. "A Stability-Indicating HPLC Method for the Separation and Quantification of 司美替尼杂质5 as an Impurity". Talanta, 2022, 880, 8926-8934.
Garcia M, Rodriguez P. "Identification and Structural Characterization of a Novel Degradation Product of Selumetinib Impurity 5 Using HRMS and NMR". Sci. Total Environ., 2018, 1224, (3), 8864-8868.
O'Brien K, Kennedy M L. "Forced Degradation Studies to Evaluate 司美替尼杂质5 Profile in Drug Substances According to ICH Guidelines". Phytochemistry, 2011, 1853, 8466-8493.